Innate Pharma S.A.

Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma full year 2022 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question at that time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press star one. Thank you. It's now my pleasure to turn today's call over to Mr. Henry Wheeler, Vice President of Investor Relations and Communications. Sir, please go ahead.

Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Enate issued a press release providing a business update for our full year 22 results. We look forward to highlighting the progress made during the year, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website. On slide two, before we start, I'd like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Turning to slide three, on today's call, we will be joined by Wanda Majubi, our Chief Executive Officer, who will then hand over to Joyce and Cara Connell, EVP and Chief Medical Officer, who will cover updates on Acutamab and Monolizumab. Yanis Morel, EVP of Business Development and Product Portfolio Strategy, will then cover some updates on partnering, and Ankit, who will then turn the call over to our CFO, Frederick Lombard, for an update on our financials.

Monda, I now hand the call over to you. Sorry, Monda, I think you might be on mute. Sorry, I'm on mute. Thank you, Henry.